Plain-English translation of NCT07433192 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes Mellitus research guide →This study is following people with type 2 diabetes who have recently started taking luseogliflozin, a new medication designed to help control blood sugar. Researchers want to learn how well this medication works in everyday medical practice — not in a strict laboratory setting — and how patients tolerate it over about 6 months. Your doctor may adjust your dose during the study if needed.
While new diabetes medications are tested in controlled trials before approval, researchers need to understand how they work in real patients with real lives. This study will show whether this medication is truly helpful and safe when used by everyday people managing type 2 diabetes.
You likely qualify if…
You likely don't qualify if…
You will take the medication as prescribed by your doctor — starting at one dose, which may be increased if needed — while researchers track how your diabetes responds over approximately 6 months. During this time, your doctor will monitor your blood sugar control, kidney function, blood pressure, and weight to see how well the treatment is working. You'll continue your regular clinic visits, and researchers will use data from those routine visits to understand the medication's real-world effectiveness and safety.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Russia
Sponsor
Servier Russia
Enrollment target
~300 participants
Started
March 2026
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ekaterina Erina
Endocrinology Research Centre
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.